Standard
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer : 6.3 years of followup. / Iversen, P; Tyrrell, C J; Kaisary, A V; Anderson, J B; Van Poppel, H; Tammela, T L; Chamberlain, M; Carroll, K; Melezinek, I.
In:
Journal of Urology, Vol. 164, No. 5, 2000, p. 1579-82.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Iversen, P, Tyrrell, CJ, Kaisary, AV, Anderson, JB, Van Poppel, H, Tammela, TL, Chamberlain, M, Carroll, K & Melezinek, I 2000, 'Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup', Journal of Urology, vol. 164, no. 5, pp. 1579-82.
APA
Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H., Tammela, T. L., Chamberlain, M., Carroll, K., & Melezinek, I. (2000). Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology, 164(5), 1579-82.
Vancouver
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology. 2000;164(5):1579-82.
Author
Iversen, P ; Tyrrell, C J ; Kaisary, A V ; Anderson, J B ; Van Poppel, H ; Tammela, T L ; Chamberlain, M ; Carroll, K ; Melezinek, I. / Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer : 6.3 years of followup. In: Journal of Urology. 2000 ; Vol. 164, No. 5. pp. 1579-82.
Bibtex
@article{f33dfbc8efef424f8d15a335ab12badc,
title = "Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup",
abstract = "Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in which patients with nonmetastatic (M0) locally advanced disease were treated with either 150 mg. bicalutamide monotherapy or castration.",
author = "P Iversen and Tyrrell, {C J} and Kaisary, {A V} and Anderson, {J B} and {Van Poppel}, H and Tammela, {T L} and M Chamberlain and K Carroll and I Melezinek",
year = "2000",
language = "English",
volume = "164",
pages = "1579--82",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier",
number = "5",
}
RIS
TY - JOUR
T1 - Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer
T2 - 6.3 years of followup
AU - Iversen, P
AU - Tyrrell, C J
AU - Kaisary, A V
AU - Anderson, J B
AU - Van Poppel, H
AU - Tammela, T L
AU - Chamberlain, M
AU - Carroll, K
AU - Melezinek, I
PY - 2000
Y1 - 2000
N2 - Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in which patients with nonmetastatic (M0) locally advanced disease were treated with either 150 mg. bicalutamide monotherapy or castration.
AB - Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in which patients with nonmetastatic (M0) locally advanced disease were treated with either 150 mg. bicalutamide monotherapy or castration.
M3 - Journal article
VL - 164
SP - 1579
EP - 1582
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 5
ER -
